Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors

Diabetes, Obesity and Metabolism

Volumn 20, Issue 3, 2018, Pages 740-744

  Fadini, Gian Paolo ^a   Bonora, Benedetta Maria ^a   Mayur, Sarangdhar ^b   Rigato, Mauro ^a   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

antidiabetic drug; database research; DPP 4 inhibitor; meta analysis; SGLT2 inhibitor

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ARTICLE; DRUG SURVEILLANCE PROGRAM; FREQUENCY; HUMAN; HYPERGLYCEMIA; INCIDENCE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TREATMENT DURATION; URINARY TRACT INFECTION; CHEMICALLY INDUCED; DRUG INTERACTION; FEMALE; GENITAL TRACT INFECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHARMACOVIGILANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TRACT INFECTIONS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85034268080     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13130     Document Type: Article

References (18)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
3. Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20:344–351.
4. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348–355.
5. Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016;34:697–700.
6. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157–166.
7. Tinahones FJ, Gallwitz B, Nordaby M, et al. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab. 2017;19:266–274.
8. Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018–2024.
9. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
10. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
11. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.
12. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.
13. Rosenstock J, Chuck L, Gonzalez-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care. 2016;39:353–362.
14. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–456.
15. Matthaei S, Aggarwal N, Garcia-Hernandez P, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016;18:1128–1133.
16. Vorisek J. Ultracytochemical localization of X-prolyl-dipeptidyl (amino)peptidase in microglobules and endoplasmic membranes accumulated in pep4-3 mutant of Saccharomyces cerevisiae. Histochemistry. 1986;84:87–96.
17. Tani S, Yuki S, Kunitake E, Sumitani JI, Kawaguchi T. Dipeptidyl peptidase IV is involved in the cellulose-responsive induction of cellulose biomass-degrading enzyme genes in Aspergillus aculeatus. Biosci Biotechnol Biochem. 2017;81:1227–1234.
18. Ohara-Nemoto Y, Nakasato M, Shimoyama Y, et al. Degradation of incretins and modulation of blood glucose levels by periodontopathic bacterial dipeptidyl peptidase 4. Infect Immun. 2017;85(9):pii: e00277–00217.